10x Genomics (TXG) Stock Looks Above Fair Value After Atera Optimism

10x Genomics stock has delivered a very strong 353.4% return over the past year, yet broader valuation checks suggest the shares are not a clear bargain at current levels. With expectations high around its Atera spatial biology platform and expanding clinical collaborations, the key issue for investors is whether the recent price move already reflects much of that optimism.

• Over the last 12 months, 10x Genomics has returned 353.4%, which puts extra focus on whether recent gains leave much room for error on valuation.
• Early demand for the Atera platform and new research partnerships can support higher growth expectations, while any disappointment in how that demand converts into sustained revenue or profitability may weigh on what investors are willing to pay.
• On Simply Wall St's broader checks, 10x Genomics is viewed as expensive rather than a clear bargain, with the stock scoring 0 out of 6 on valuation.

For investors, the debate is whether 10x Genomics' recent surge and growth story justify paying up at these valuation levels or call for more caution.

10x Genomics delivered 353.4% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Does 10x Genomics Look Pricey on Sales?

P/S is often a useful way to look at a company like 10x Genomics because revenue is available even when earnings are thin or volatile. Here the numbers point to a rich valuation. The stock trades on a P/S of 13.5x, which is roughly three times the Life Sciences industry average of 4.5x and also well above the peer group average of 5.3x.

The fair P/S ratio implied by Simply Wall St's model is 6.1x, which already factors in 10x Genomics' growth profile, margins, size and risks. That sits well below the current 13.5x, so the shares trade at a clear premium to what the model suggests would be reasonable. Despite the recent lift in sentiment after management raised 2026 revenue guidance on strong Atera demand, the current P/S implies a lot of that optimism is already priced into the stock.

On this P/S yardstick, 10x Genomics stock screens as overvalued compared with both its own fair ratio and typical levels in the Life Sciences industry.

See what the numbers say about this price — find out in our valuation breakdown.

The 10x Genomics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for 10x Genomics leaves off. They spell out which assumptions about growth, margins and future earnings would need to hold for the stock to be worth materially more or less than today's price, and each one turns fair value into a clear thesis about the underlying business that you can watch over time instead of treating it as a one off snapshot. Narratives are available on Simply Wall St's Community page, where you can explore different angles on 10x Genomics' outlook.

One of the top community narratives on 10x Genomics: 29% overvalued

"Given the current share price of $62.19, the analyst price target of $49.54 is 25.5% lower..."

Read one of the top narratives on 10x Genomics

Do you think there's more to the story for 10x Genomics? Head over to our Community to see what others are saying!

The Bottom Line

For 10x Genomics, current market multiples point to an overvalued stock rather than one that obviously compensates you for execution risk. The key question is whether Atera demand and clinical partnerships eventually support revenue and margin outcomes strong enough to sustain this premium. If that plays out, today’s pricing may prove reasonable. If growth or profitability fall short, the current valuation leaves less room for disappointment.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com